Riskpilot← Back to searchSign inGet full accessCell4Cure AB
ABActiveOrg 5594457979Gustav Iii:S Boulevard 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 20230 employees
Revenue 2024
SEK 37K
EBITDA margin
-1422.0%
Equity ratio
90.4%
Financial strength
Net profit 2024
SEK -532K
0 employees
| Revenue | SEK 37K | — |
| EBITDA | SEK -532K | — |
| Net profit | SEK -532K | — |
| Total assets | SEK 1,2M | — |
| Equity | SEK 1,1M | — |
| Employees | 0 | — |
Legal name
Cell4Cure AB
Org number
5594457979
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25 augusti 2023
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget skall bedriva forskning och utveckling för att identifiera och utveckla nya läkemedel. Bolaget ska verka inom olika sjukdomsområden, innefattande men inte begränsat till autoimmuna sjukdomar, transplantation och patienter som utvecklat antikroppar mot läkemedel. Vidare kommer bolagets verksamhet att innefatta patentering, tillverkning och kommersialisering av nya läkemedel samt därmed förenlig verksamhet.
Address
Gustav Iii:S Boulevard 10
Email
hamid.bakhshi@cell4cure.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | 37 |
| Staff expenses | — |
| EBITDA | −532 |
| Depreciation & amort. | — |
| EBIT | −532 |
| Net financials | 0 |
| Profit before tax | −532 |
| Tax | — |
| Net profit | −532 |
| Item | 2024 |
|---|---|
| Total assets | 1 215 |
| Equity | 1 098 |
| Long-term debt | — |
| Short-term debt | 117 |
| Total debt | 117 |
EBITDA margin
-1422.0%
This company
15.8%
Market median
-9100% vs market
20242024
Equity ratio
90.4%
This company
38.2%
Market median
+137% vs market
20242024
Return on equity
-48.5%
This company
18.4%
Market median
-364% vs market
20242024
Net profit margin
-1421.7%
This company
8.1%
Market median
-17652% vs market
20242024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20242024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20242024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-08-25 – 2024-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
OG Audit | Audit | 2026 | — | — |
CE Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cell4Cure AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Oliver Georg Rohde | Audit | 0 companies |
| Christina Elisabeth Herder | Chief Executive Officer | 0 companies |
| Fredrik Ralf Erik Gustavsson | Board of Directors | 0 companies |
| Eva Agneta Edberg | Chairman | 0 companies |
| Hamid Baradaran Bakhshi | Board of Directors | 0 companies |
| Sara Nikman | Board of Directors | 0 companies |
| Jan Anders Holgersson | Board of Directors | 0 companies |